栄研化学の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2021/07/29 | 2,322 | 2,340 | 2,279 | 2,289 | -31 | -1.3% | 224,400 |
2021/07/28 | 2,223 | 2,337 | 2,219 | 2,320 | +70 | +3.1% | 455,500 |
2021/07/27 | 2,249 | 2,298 | 2,226 | 2,250 | +63 | +2.9% | 559,900 |
2021/07/26 | 2,206 | 2,219 | 2,162 | 2,187 | +25 | +1.2% | 182,800 |
2021/07/21 | 2,155 | 2,163 | 2,138 | 2,162 | +45 | +2.1% | 90,500 |
2021/07/20 | 2,117 | 2,136 | 2,104 | 2,117 | -7 | -0.3% | 86,200 |
2021/07/19 | 2,136 | 2,138 | 2,108 | 2,124 | -18 | -0.8% | 95,800 |
2021/07/16 | 2,140 | 2,153 | 2,120 | 2,142 | +17 | +0.8% | 57,800 |
2021/07/15 | 2,152 | 2,162 | 2,125 | 2,125 | -48 | -2.2% | 74,900 |
2021/07/14 | 2,173 | 2,185 | 2,170 | 2,173 | -4 | -0.2% | 39,300 |
2021/07/13 | 2,172 | 2,188 | 2,159 | 2,177 | +7 | +0.3% | 64,400 |
2021/07/12 | 2,153 | 2,178 | 2,148 | 2,170 | +49 | +2.3% | 87,000 |
2021/07/09 | 2,090 | 2,128 | 2,090 | 2,121 | +15 | +0.7% | 144,500 |
2021/07/08 | 2,120 | 2,137 | 2,100 | 2,106 | -23 | -1.1% | 79,700 |
2021/07/07 | 2,091 | 2,132 | 2,083 | 2,129 | +24 | +1.1% | 77,600 |
2021/07/06 | 2,147 | 2,147 | 2,098 | 2,105 | -27 | -1.3% | 66,400 |
2021/07/05 | 2,156 | 2,157 | 2,132 | 2,132 | -37 | -1.7% | 46,600 |
2021/07/02 | 2,153 | 2,173 | 2,150 | 2,169 | +27 | +1.3% | 61,100 |
2021/07/01 | 2,147 | 2,151 | 2,118 | 2,142 | -7 | -0.3% | 62,200 |
2021/06/30 | 2,180 | 2,184 | 2,147 | 2,149 | +19 | +0.9% | 77,900 |
2021/06/29 | 2,151 | 2,151 | 2,121 | 2,130 | -32 | -1.5% | 98,900 |
2021/06/28 | 2,202 | 2,209 | 2,155 | 2,162 | -58 | -2.6% | 137,900 |
2021/06/25 | 2,187 | 2,221 | 2,181 | 2,220 | +45 | +2.1% | 134,000 |
2021/06/24 | 2,163 | 2,187 | 2,158 | 2,175 | +17 | +0.8% | 84,200 |
2021/06/23 | 2,169 | 2,176 | 2,154 | 2,158 | -5 | -0.2% | 49,100 |
2021/06/22 | 2,147 | 2,166 | 2,136 | 2,163 | +53 | +2.5% | 90,900 |
2021/06/21 | 2,085 | 2,131 | 2,080 | 2,110 | -7 | -0.3% | 134,700 |
2021/06/18 | 2,165 | 2,170 | 2,109 | 2,117 | -42 | -1.9% | 154,600 |
2021/06/17 | 2,165 | 2,179 | 2,152 | 2,159 | -3 | -0.1% | 49,500 |
2021/06/16 | 2,138 | 2,162 | 2,132 | 2,162 | -4 | -0.2% | 93,200 |
2021/06/15 | 2,178 | 2,185 | 2,162 | 2,166 | -10 | -0.5% | 60,000 |
2021/06/14 | 2,195 | 2,198 | 2,164 | 2,176 | -10 | -0.5% | 47,300 |
2021/06/11 | 2,169 | 2,194 | 2,169 | 2,186 | +17 | +0.8% | 93,300 |
2021/06/10 | 2,155 | 2,183 | 2,153 | 2,169 | +1 | ±0% | 45,200 |
2021/06/09 | 2,129 | 2,181 | 2,129 | 2,168 | +22 | +1% | 61,700 |
2021/06/08 | 2,117 | 2,149 | 2,107 | 2,146 | +52 | +2.5% | 131,900 |
2021/06/07 | 2,117 | 2,119 | 2,093 | 2,094 | -4 | -0.2% | 95,300 |
2021/06/04 | 2,106 | 2,115 | 2,085 | 2,098 | +12 | +0.6% | 91,600 |
2021/06/03 | 2,078 | 2,093 | 2,067 | 2,086 | +15 | +0.7% | 73,900 |
2021/06/02 | 2,105 | 2,105 | 2,063 | 2,071 | -53 | -2.5% | 138,200 |
2021/06/01 | 2,154 | 2,154 | 2,099 | 2,124 | -20 | -0.9% | 97,400 |
2021/05/31 | 2,162 | 2,173 | 2,127 | 2,144 | -38 | -1.7% | 105,700 |
2021/05/28 | 2,200 | 2,215 | 2,161 | 2,182 | -5 | -0.2% | 104,100 |
2021/05/27 | 2,188 | 2,203 | 2,163 | 2,187 | +18 | +0.8% | 357,000 |
2021/05/26 | 2,187 | 2,196 | 2,169 | 2,169 | -30 | -1.4% | 90,300 |
2021/05/25 | 2,177 | 2,200 | 2,174 | 2,199 | +16 | +0.7% | 78,900 |
2021/05/24 | 2,189 | 2,190 | 2,165 | 2,183 | -10 | -0.5% | 72,000 |
2021/05/21 | 2,155 | 2,193 | 2,148 | 2,193 | +54 | +2.5% | 156,900 |
2021/05/20 | 2,109 | 2,142 | 2,107 | 2,139 | +42 | +2% | 88,900 |
2021/05/19 | 2,079 | 2,109 | 2,077 | 2,097 | +5 | +0.2% | 108,300 |
801~
850
件表示中 / 6826件
類似銘柄と比較する
現在ご覧いただいている「栄研化」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
栄研化 | 232,200円 | +0.4% | -8.4% | 2.28% | 30.69倍 | 1.75倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
ネクセラファーマ | 121,300円 | +197.7% | - | 0.00% | 49.57倍 | 1.58倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
杏林製薬 | 151,800円 | +3.2% | +4.5% | 3.43% | 17.44倍 | 0.67倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
JCRファーマ | 67,900円 | -3.7% | -36.7% | 2.95% | 23.03倍 | 1.50倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
サンバイオ | 101,300円 | - | - | 0.00% | - | 51.01倍 |
|
脳疾患向け再生細胞薬の開発・製造・販売目指すバイオベンチャー。米国で創業し日本に逆上陸 |
市場注目の銘柄
チャート関連のコラム